✦ LIBER ✦

W1106 Increased BMI Is Not Associated with Dose Escalation or Failure of Adalimumab Therapy in Crohn's Disease

✍ Scribed by Qumseya, Bashar; Naik, Amar S.; Ananthakrishnan, Ashwin N.; Zadvornova, Yelena; Skaros, Susan; Johnson, Kathryn; Perera, Lilani P.; Binion, David G.; Issa, Mazen

Book ID: 122652008
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)63020-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Periperative infliximab and/or immunomod

Periperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease

✍ Colombel, Jean F.; Loftus, Edward V.; Tremaine, William J.; Pemberton, John H.; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 264 KB

Is Weight-Based Dosing of Adalimumab or

Is Weight-Based Dosing of Adalimumab or Certolizumab Pegol Associated With Higher Efficacy in Patients With Crohn's Disease (CD)?

✍ Wojciech Blonski; Mark T. Osterman; Colleen M. Brensinger; Anna M. Buchner; Gary 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 220 KB